Cocrystal Pharma Inc. (NASDAQ: COCP) Starts Presentation at NobleCon16
Cocrystal Pharma (NASDAQ: COCP) is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses and noroviruses. The company is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor currently being evaluated in a phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of four to six weeks. Cocrystal recently entered into an exclusive worldwide license and collaboration agreement with Merck & Co., Inc. to discover and develop certain proprietary influenza A/B antiviral agents. CC-42344, the company’s molecule for the treatment of…







